1562995-68-9

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 633328-40-2 3-iodo-1H-pyrazolo[4,3-b]pyridine 

Downstream Products

• 1562995-62-3 methyl 4-(1-(2-chloro-6-cyclopropylbenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoate 
• 1562995-11-2 4-(1-(2-chloro-6-cyclopropylbenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoic acid 
• 1562995-86-1 methyl 4-(1-(4-bromo-2-chloro-6-methylbenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoate 
• 1562995-87-2 4-(1-(2-chloro-4-hydroxy-6-methylbenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoic acid 
• 1562995-40-7 4-(1-(2-chloro-4-(2-methoxyethoxy)-6-methylbenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoic acid 
• 1562995-88-3 methyl 4-(1-(2-chloro-6-methyl-4-morpholinobenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoate 
• 1562995-41-8 4-(1-(2-chloro-6-methyl-4-morpholinobenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoic acid 
• 1562995-91-8 methyl 4-(1-(4-amino-2-chloro-6-methylbenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoate 
• 1562995-93-0 3-fluoro-4-(1H-pyrazolo[4,3-b]pyridin-3-yl)benzoic acid 
• 1562995-45-2 4-(1-(2-chloro-6-cyclopentylbenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoic acid 
• 1562995-94-1 methyl 4-(1-(2-chloro-6-cyclohexylbenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoate 
• 1562995-46-3 4-(1-(2-chloro-6-cyclohexylbenzoyl)-1H-pyrazolo[4,3-b]pyridin-3-yl)-3-fluorobenzoic acid 
• 1562995-69-0 methyl 3-fluoro-4-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-b]pyridin-3-yl)benzoate 

Relevant academic research and scientific papers

HETEROARYL SUBSTITUTED BENZOIC ACIDS AS RORGAMMAT INHIBITORS AND USES THEREOF

The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.

4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.